We serve Chemical Name:2-methylbutan-2-ylurea CAS:625-15-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methylbutan-2-ylurea
CAS.NO:625-15-0
Synonyms:tert-Pentyl-harnstoff;tert-Amylurea;t-Amylharnstoff;Urea,1-dimethylpropyl);Urea,tert-pentyl;tert.-Amylharnstoff;N-<1,1-Dimethyl-propyl>-harnstoff;tert-pentyl-urea
Molecular Formula:C6H14N2O
Molecular Weight:130.18800
HS Code:2924199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:185.7ºC at 760 mmHg
Density:0.948g/cm3
Index of Refraction:1.451
PSA:55.12000
Exact Mass:130.11100
LogP:1.93450
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like tert-Pentyl-harnstoff chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-pentyl-urea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,-harnstoff Use and application,t-Amylharnstoff technical grade,usp/ep/jp grade.
Related News: He was the partner of a 38-year-old Chinese woman who was travelling with him. She was the first confirmed case reported in the Philippines. 2-methylbutan-2-ylurea manufacturer The new rules started Saturday — however if you’re an Australian citizen, permanent resident or their immediate family, or an aircrew member who has been using appropriate protective equipment, you’re exempt. 2-methylbutan-2-ylurea supplier Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control. 2-methylbutan-2-ylurea vendor This is how an API becomes a medicine. 2-methylbutan-2-ylurea factory The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.